Investigating AlloMax Breast Reconstruction Lawsuits
Investigations involving AlloMax breast reconstruction lawsuits are part of broader litigation concerning mesh and acellular dermal matrix (ADM) products used in implant-based breast reconstruction, revision procedures, and internal support techniques sometimes referred to as “internal bra” surgery.
These lawsuits generally involve allegations concerning postoperative complications, revision surgery, product labeling, informed consent, complication reporting, and the use of mesh or scaffold materials during breast procedures.
FDA communications issued in 2021 discussed differing complication outcomes reported among certain ADM products used in implant-based breast reconstruction procedures.
Those communications, along with published medical literature and adverse event reporting, are frequently referenced in breast mesh litigation involving postoperative complications such as infection, wound-healing problems, implant loss, seroma formation, capsular contracture, and revision surgery.
FDA communications involving mesh and ADM products have also addressed product labeling, reconstruction outcomes, and the use of mesh materials in implant-based breast procedures.
Manufacturers named in litigation dispute allegations that their products were defective, improperly marketed, or inadequately labeled.
Lawsuits involving AlloMax are typically filed by patients who underwent breast reconstruction, augmentation, revision surgery, or mesh-assisted support procedures and later required additional medical treatment after postoperative complications developed.
Reported complications discussed in litigation may include chronic pain, infection, implant-position problems, wound breakdown, tissue necrosis, fluid collections, cosmetic deformity, implant removal, or additional revision procedures.
Common allegations raised in breast mesh lawsuits may include:
- Allegations that product labeling or warnings did not adequately address certain complication risks associated with mesh-assisted breast procedures
- Allegations involving postoperative complications, implant loss, revision surgery, or reconstructive failure following implantation
- Allegations concerning product performance, implant support, or postoperative healing outcomes
- Allegations involving mesh migration, implant-position changes, scar tissue complications, or reconstructive deformities
- Allegations concerning the use of mesh materials in implant-based breast reconstruction or internal support procedures
Many patients pursuing breast mesh claims report undergoing additional surgeries, prolonged wound care, implant exchange procedures, or reconstruction revisions following postoperative complications.
Individuals seeking legal review in these cases often pursue compensation related to medical expenses, future treatment needs, lost income, chronic pain, scarring, disfigurement, or other documented damages associated with their postoperative course.
Breast mesh litigation involving AlloMax and other ADM products remains ongoing, and no court has entered findings establishing liability or wrongdoing related to the allegations described in pending lawsuits.
What Is AlloMax?
AlloMax is an acellular dermal matrix (ADM) product derived from donated human tissue that has been processed to remove living cells while preserving a collagen-based structural framework.
In implant-based breast reconstruction and some revision procedures, surgeons may use ADM products such as AlloMax to reinforce soft tissue, support the implant pocket, or help stabilize a tissue expander following mastectomy or reconstructive surgery.
Some surgeons also use ADM materials as part of internal support techniques sometimes referred to as “internal bra” procedures, in which the material is positioned within the breast to provide additional structural reinforcement during healing.
AlloMax has been manufactured and distributed by companies associated with C. R. Bard, which later became part of Becton, Dickinson and Company (BD). In lawsuits involving AlloMax, BD is commonly named among the defendants.
ADM products such as AlloMax have been used in a variety of soft-tissue reinforcement procedures, including implant-based breast reconstruction. FDA communications involving ADM and mesh products have discussed reconstruction outcomes, complication reporting, and product labeling related to implant-based breast procedures.
During healing, ADM materials are intended to function as a supportive scaffold that interacts with surrounding tissue over time.
As with other implant-based breast procedures, some patients later report complications such as infection, wound-healing problems, capsular contracture, implant-position changes, fluid collections, pain, or the need for revision surgery.
Litigation involving AlloMax generally focuses on postoperative complications, revision procedures, product labeling, complication reporting, informed consent, and the medical treatment required after surgery.
How AlloMax Is Used in Breast Reconstruction and Internal Bra Procedures
In implant-based breast reconstruction, AlloMax may be used to help support a tissue expander or breast implant following mastectomy or revision surgery.
Some plastic surgeons use ADM materials such as AlloMax as part of an internal support technique sometimes referred to as an “internal bra,” where the material is sutured into place to reinforce soft tissue during healing.
AlloMax is one of several acellular dermal matrix products used in implant-based reconstruction and revision procedures involving breast tissue and implant support structures.
Similar techniques may also be used during revision surgery or alongside breast lift procedures to provide additional lower-pole support or reinforce weakened tissue.
AlloMax may be used in several ways during reconstruction or revision procedures, including:
- Secured to the chest wall or muscle to help position a tissue expander or implant
- Placed along the lower pole of the breast to provide internal support
- Used to reinforce weakened tissue during revision or reconstructive procedures
- Implanted alongside other reconstructive materials during complex breast surgeries
Potential Injuries Linked to Breast Mesh and Acellular Dermal Matrices
Postoperative complications can occur after implant-based breast reconstruction, augmentation, revision procedures, and surgeries involving mesh or acellular dermal matrix (ADM) materials.
Patients undergoing mesh-assisted breast procedures may experience symptoms such as swelling, firmness, pain, wound-healing problems, implant-position changes, or cosmetic concerns during the recovery process or later postoperative period.
ADM products and other support materials are intended to provide structural reinforcement during healing, but postoperative outcomes can vary depending on patient anatomy, tissue quality, surgical technique, infection risk, radiation exposure, implant placement, and other medical or surgical factors.
When complications develop, infection, wound breakdown, fluid collections, or scar tissue formation may affect the implant pocket, surrounding tissue, or reconstructive outcome.
In some cases, these complications may require additional treatment, drainage procedures, revision surgery, implant exchange, or implant removal.
Some patients also experience tissue damage related to impaired blood supply, pressure on thin skin flaps, delayed wound healing, or postoperative inflammation.
Severe complications may involve tissue necrosis requiring debridement, wound care, or additional reconstructive procedures.
If implants or surrounding tissue become unstable, exposed, or severely compromised during the postoperative course, surgeons may recommend implant removal or staged reconstruction changes as part of ongoing treatment.
Reported complications associated with implant-based breast procedures involving mesh or acellular dermal matrix materials may include:
- Surgical site infection or deep infection involving the implant pocket
- Tissue necrosis affecting skin flaps or surrounding tissue
- Tissue damage associated with wound breakdown or compromised circulation
- Seroma or persistent fluid collections requiring aspiration or drains
- Hematoma or postoperative bleeding requiring surgical evacuation
- Wound dehiscence, delayed healing, or incision separation
- Implant exposure or reconstructive complications requiring additional treatment
- Implant malposition, asymmetry, or contour irregularities
- Capsular contracture or painful scar tissue formation around the implant
- Chronic pain, burning sensations, numbness, or hypersensitivity
- Shifting or movement of implanted support material
- Loss of support or reconstructive changes requiring revision surgery
- Revision surgery, washout procedures, or staged reconstruction changes
- Explantation, including implant removal or delayed re-implantation
- Permanent scarring, contour defects, or disfigurement following complications
Not every postoperative complication establishes a product-related claim, and many outcomes depend on the patient’s medical history, tissue quality, healing response, and overall surgical circumstances.
In breast mesh litigation, operative reports, product-identification records, postoperative treatment history, revision surgery documentation, and complication timelines often become central to evaluating the medical course and allegations involved in a particular case.
These records are commonly reviewed to assess the severity of complications, the treatment required after surgery, and the progression of the patient’s postoperative recovery.
FDA Communications on Breast Mesh and Acellular Dermal Matrices
FDA communications involving surgical mesh and acellular dermal matrix (ADM) products are frequently referenced in breast mesh litigation because they discuss product labeling, complication reporting, and published clinical outcome data involving implant-based breast reconstruction procedures.
FDA communications issued in 2021 and 2023 addressed reconstruction outcomes associated with certain ADM and mesh products used in implant-based breast procedures.
These communications discussed topics including postoperative complications, reoperation rates, implant loss, product labeling, and clinical data reported in published literature and adverse event reporting systems.
The FDA has also issued communications to health care providers regarding labeling updates for certain BD mesh products used for soft-tissue reinforcement applications.
The communications and patient resources below are among the FDA materials most commonly referenced in litigation and clinical discussions involving mesh-assisted breast procedures:
These FDA communications do not determine whether a specific patient’s postoperative complications were caused by a particular product.
In litigation and claim review, they are typically considered alongside operative reports, pathology findings, complication timelines, revision history, and other medical evidence related to the patient’s treatment course.
Do You Qualify for a Breast Mesh Lawsuit?
Breast mesh lawsuits are evaluated on a case-by-case basis, and any potential compensation depends on factors such as the available medical evidence, the severity of the complications, the treatment required after surgery, and the overall impact on the patient’s health, employment, and quality of life.
Many claims under investigation involve mesh or acellular dermal matrix (ADM) materials used during implant-based breast reconstruction, breast augmentation, revision procedures, breast lift surgery, or internal support techniques sometimes referred to as “internal bra” procedures.
Legal review often focuses on whether the patient experienced serious postoperative complications that required additional medical treatment, revision surgery, implant exchange, implant removal, prolonged wound care, or other reconstructive procedures following implantation.
Product identification is frequently an important issue in breast mesh litigation. Operative reports, implant logs, device labels, Unique Device Identifier (UDI) information, billing records, and pathology findings may help confirm which mesh or ADM product was used during surgery.
If those records are not immediately available, hospitals, surgical centers, and treating physicians may still maintain operative reports, implant records, or product documentation that can be requested as part of the review process.
Attorneys evaluating these claims generally review the patient’s medical timeline, operative history, complication records, revision procedures, and documented damages to determine whether the available evidence supports further investigation.
Timing may also matter because statutes of limitation vary by state and may depend on when the alleged injury occurred or when postoperative complications were discovered.
A claim review typically focuses on documented medical evidence, the progression of postoperative complications, the treatment required after surgery, and whether the available records support the allegations being investigated.
Gathering Evidence for an AlloMax Breast Mesh Lawsuit
Strong evidence is essential in a breast mesh lawsuit because it documents exactly which product was used and how your injuries developed over time.
Medical records, imaging, and operative notes help establish a clear connection between the mesh and the complications you experienced.
To start an internal bra mesh claim, you typically need proof that you received a breast mesh implant, proof of your injuries, and documentation showing the damages you suffered.
A well-supported breast mesh claim is built on records that identify the product, capture the complication timeline, and show what treatment and losses followed.
Evidence in these cases may include:
- Operative report and surgical notes describing where the mesh was placed and how it was secured
- Implant log, device stickers, and any Unique Device Identifier (UDI) information tied to AlloMax
- Device lot number, catalog number, and manufacturer information from the facility record
- Post-operative visit notes documenting symptoms, wound issues, or changes in breast shape or pain levels
- Imaging records when relevant, such as ultrasound, MRI, or CT scans used to evaluate fluid collections or implant problems
- Lab results and culture reports if infection was suspected or confirmed
- Hospitalization records, IV antibiotic records, and wound care documentation
- Records of revision surgery, washouts, debridement, implant exchange, or implant removal
- Photographs of wound breakdown, tissue loss, or visible complications when available
- Itemized medical bills and insurance statements showing treatment costs
- Employment records showing lost wages or time off work due to complications and recovery
- A written timeline of symptoms and treatment milestones to align with the medical chart
Potential Damages in Breast Mesh Lawsuits
Damages are the legally recognized losses a person claims after an injury, and they can include both financial costs and the broader impact the complications had on daily life.
In breast mesh lawsuits, damages often reflect the real-world consequences of additional surgeries, extended recovery, and permanent changes to the body.
Breast mesh lawyers review medical records, billing statements, employment documentation, and the treatment timeline to assess what costs have already occurred and what care may be needed going forward.
They also evaluate non-economic harm, including chronic pain, scarring, and emotional distress tied to disfigurement, repeated procedures, or loss of reconstruction outcomes.
The goal is to document damages in a way that is specific, provable, and consistent with the individual’s medical course.
Damages in these cases may include:
- Past medical expenses related to complications, including hospital care, antibiotics, and wound treatment
- Future medical expenses, including revision surgery, reconstruction planning, and follow-up care
- Costs of implant removal, implant exchange, or staged reconstruction after failure or infection
- Lost wages and reduced earning capacity from time away from work or long-term limitations
- Physical pain, including chronic pain and ongoing sensitivity at the surgical site
- Emotional distress related to disfigurement, loss of reconstruction progress, or repeat surgeries
- Scarring, tissue loss, and permanent disfigurement
- Out-of-pocket costs such as travel for specialty care, prescriptions, and medical supplies
- Loss of enjoyment of life due to limitations, ongoing symptoms, or persistent complications
TorHoerman Law: Investigating Lawsuits Related to Breast Mesh Implants
Breast mesh implant claims often come down to documentation, a clear medical timeline, and proof of which product was implanted.
When complications lead to infection, tissue loss, revision surgery, or implant removal, the consequences are not theoretical, they show up in operative notes, hospital records, and long-term treatment plans.
TorHoerman Law is investigating breast mesh implant lawsuits involving products used in reconstruction, augmentation, revision, and internal bra procedures, including cases where patients report serious complications after mesh placement.
If you believe a breast mesh implant contributed to your injuries, TorHoerman Law can review your surgical records, complication history, and damages to determine whether the evidence supports a claim.
Contact TorHoerman Law to request a case review and learn whether your situation may qualify for legal action.
